Apogee execs join Paragon to scale its R&D, company creation engine
Some people would think about taking a break for several quarters after selling a biotech for $10.9 billion. Michael Henderson and five of his fellow executives from Apogee Therapeutics are not fading ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.